- Home
- SPCE vs CGEN Comparison
SPCE vs CGEN Comparison
Compare SPCE & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCE
- CGEN
- Stock Information
- Founded
- SPCE 2017
- CGEN 1993
- Country
- SPCE United States
- CGEN Israel
- Employees
- SPCE N/A
- CGEN N/A
- Industry
- SPCE Transportation Services
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPCE Consumer Discretionary
- CGEN Health Care
- Exchange
- SPCE Nasdaq
- CGEN Nasdaq
- Market Cap
- SPCE 187.2M
- CGEN 125.3M
- IPO Year
- SPCE N/A
- CGEN 2000
- Fundamental
- Price
- SPCE $3.31
- CGEN $1.34
- Analyst Decision
- SPCE Hold
- CGEN
- Analyst Count
- SPCE 6
- CGEN 0
- Target Price
- SPCE $9.54
- CGEN N/A
- AVG Volume (30 Days)
- SPCE 2.1M
- CGEN 238.3K
- Earning Date
- SPCE 11-05-2025
- CGEN 11-11-2025
- Dividend Yield
- SPCE N/A
- CGEN N/A
- EPS Growth
- SPCE N/A
- CGEN N/A
- EPS
- SPCE N/A
- CGEN N/A
- Revenue
- SPCE $1,698,000.00
- CGEN $22,144,000.00
- Revenue This Year
- SPCE N/A
- CGEN N/A
- Revenue Next Year
- SPCE $2,869.26
- CGEN $159.40
- P/E Ratio
- SPCE N/A
- CGEN N/A
- Revenue Growth
- SPCE N/A
- CGEN N/A
- 52 Week Low
- SPCE $2.18
- CGEN $1.13
- 52 Week High
- SPCE $8.19
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- SPCE 54.16
- CGEN 35.25
- Support Level
- SPCE $3.12
- CGEN $1.39
- Resistance Level
- SPCE $3.42
- CGEN $1.47
- Average True Range (ATR)
- SPCE 0.15
- CGEN 0.06
- MACD
- SPCE 0.03
- CGEN -0.00
- Stochastic Oscillator
- SPCE 65.00
- CGEN 5.88
About SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.